Cancer Letters, Год журнала: 2025, Номер unknown, С. 217726 - 217726
Опубликована: Апрель 1, 2025
Язык: Английский
bioRxiv (Cold Spring Harbor Laboratory), Год журнала: 2025, Номер unknown
Опубликована: Фев. 27, 2025
Knowledge discovery in databases (KDD) can contribute to translational research, also known as medicine, by bridging the gap between vitro and vivo studies clinical applications. Here, we propose a 'systems modeling' workflow for KDD. This framework includes data collection of composition model (various research models) processing (proteomics) analytical (bioinformatics, artificial intelligence/machine leaning pattern evaluation), knowledge presentation, feedback loops hypothesis generation validation. We applied this study pancreatic ductal adenocarcinoma (PDAC). Through approach, identified common proteins human PDAC various models (cells, spheroids organoids) (mouse mice). Accordingly, hypothesized potential targets on hub related signaling pathways, specific signature high topological proteins. Thus, suggest that systems modeling be valuable method KDD, facilitating general particular PADA case.
Язык: Английский
Процитировано
1
International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(6), С. 2620 - 2620
Опубликована: Март 14, 2025
Immune checkpoint inhibitors (ICIs) have transformed the therapeutic landscape for several malignancies, but their efficacy in unresectable pancreatic adenocarcinoma remains uncertain. This systematic review aimed to evaluate effectiveness and safety of ICIs this context, focusing on overall survival (OS), progression-free (PFS), objective response rate (ORR), disease control (DCR), toxicity. A comprehensive search MEDLINE, EMBASE, CENTRAL, Scopus identified 34 eligible studies, including randomized controlled trials observational cohorts. Quantitative synthesis involved 21 studies comprising 937 patients, with additional qualitative analyses biomarker-driven subgroups early-phase trials. The median OS across was 8.65 months, while PFS 2.55 months. ORR DCR were 16.2% 50.3%, respectively, grade ≥3 treatment-related adverse events occurring 22% patients. Promising outcomes observed MSI-H/dMMR populations, although these represented only 1–2% cases. Combination strategies chemotherapy demonstrated synergistic potential lacked definitive evidence due heterogeneity absence phase III showed a manageable toxicity profile, highlighting feasibility selected Future research should focus overcoming tumor microenvironment barriers identifying biomarkers optimize responsiveness expand applicability cancer.
Язык: Английский
Процитировано
1
The Journal of Liquid Biopsy, Год журнала: 2025, Номер unknown, С. 100293 - 100293
Опубликована: Март 1, 2025
Liquid biopsy (LB) has emerged as a transformative tool in oncology, providing minimally invasive approach for tumor detection, molecular characterization, and real-time treatment monitoring. By analyzing circulating DNA (ctDNA), cells (CTCs), extracellular vesicles (EVs), microRNA (miRNA), LB enables comprehensive profiling without the need traditional tissue biopsies. Over past decade, research this field expanded exponentially, leading to integration of into clinical practice specific cancer types, including lung breast cancer. In 2024, Journal Biopsy (JLB) published innovative studies exploring latest advancements technologies, biomarkers, their applications minimal residual disease (MRD) monitoring, therapy response assessment. This review synthesizes recent findings on role monitoring across different with particular focus newly context within translational research. Additionally, it highlights emerging techniques such fragmentomics, artificial intelligence, multiomics, paving way more precise, personalized decisions. Despite these advancements, challenges remain standardizing methodologies, optimizing validation, integrating routine oncological workflows. mini-review evolving landscape its potential revolutionize diagnosis, therapeutic decision-making, ushering new era precision oncology.
Язык: Английский
Процитировано
1
The Lancet, Год журнала: 2025, Номер 405(10485), С. 1182 - 1202
Опубликована: Апрель 1, 2025
Язык: Английский
Процитировано
1
Cancer Letters, Год журнала: 2025, Номер unknown, С. 217726 - 217726
Опубликована: Апрель 1, 2025
Язык: Английский
Процитировано
1